Adaptimmune Therapeutics PLC ADAP
We take great care to ensure that the data presented and summarized in this overview for Adaptimmune Therapeutics PLC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADAP
View all-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$22.2 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$16.2 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$10.1 Million1.24% of portfolio
-
Baillie Gifford & CO16.8MShares$9.9 Million0.01% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR13.3MShares$7.85 Million0.46% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA10MShares$5.9 Million0.56% of portfolio
-
Mpm Asset Management LLC Cambridge, MA5.56MShares$3.28 Million3.63% of portfolio
-
Bio Impact Capital LLC Cambridge, MA5.1MShares$3.01 Million0.76% of portfolio
-
Bank Of America Corp Charlotte, NC4.65MShares$2.75 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.43MShares$1.43 Million0.08% of portfolio
Latest Institutional Activity in ADAP
Top Purchases
Top Sells
About ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Transactions at ADAP
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 18
2024
|
Cintia Piccina Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
24,531
-39.05%
|
$0
$0.93 P/Share
|
Jan 17
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,908
-40.39%
|
$0
$0.67 P/Share
|
Jan 17
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
18,114
-40.39%
|
$0
$0.67 P/Share
|
Jan 17
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,276
-40.39%
|
$0
$0.67 P/Share
|
Jan 17
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,080
-40.15%
|
$0
$0.67 P/Share
|
Jan 16
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,681
-39.99%
|
$0
$0.79 P/Share
|
Jan 16
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,681
-39.99%
|
$0
$0.79 P/Share
|
Jan 16
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,287
-40.48%
|
$0
$0.79 P/Share
|
Jan 16
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,304
-39.75%
|
$0
$0.79 P/Share
|
Jan 12
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
5,220
-39.87%
|
$0
$0.85 P/Share
|
Jan 12
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,257
-39.54%
|
$0
$0.85 P/Share
|
Jan 12
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,220
-39.87%
|
$0
$0.85 P/Share
|
Jan 12
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,799
-39.71%
|
$0
$0.85 P/Share
|
Jan 11
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,009
-39.64%
|
$0
$0.84 P/Share
|
Jan 11
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,945
-39.37%
|
$0
$0.84 P/Share
|
Jan 11
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,009
-39.64%
|
$0
$0.84 P/Share
|
Jan 11
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,009
-39.64%
|
$0
$0.84 P/Share
|
Sep 01
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,403
-41.06%
|
$0
$0.78 P/Share
|
Aug 01
2023
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
3,096
-39.62%
|
$0
$0.91 P/Share
|
Jul 10
2023
|
Garry E Menzel Director |
SELL
Open market or private sale
|
Direct |
47,702
-38.86%
|
$0
$0.91 P/Share
|
Last 12 Months Summary
Open market or private sale | 190K shares |
---|